Abstract
We studied the combined anti-human immunodeficiency virus type 1 (HIV-1) effects of a derivative of stroma-derived factor 1beta (SDF-1beta), Met-SDF-1beta, and a modified form of RANTES, aminooxypentane (AOP)-RANTES. The antiviral agents were tested singly or in combination at 95 and 99% virus inhibitory concentrations. Clinical R5 and X4 HIV-1 isolates were used. AOP-RANTES inhibited R5 but not X4 viruses, whereas Met-SDF-1beta had the opposite effect. Combinations of these compounds inhibited mixed infections with R5 and X4 viruses (95 to 99%), whereas single drugs were less inhibitory (32 to 61%). Combinations of R5 and X4 inhibitors are promising and deserve further evaluation.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Amino Acid Sequence
-
Anti-HIV Agents / pharmacology*
-
Anti-HIV Agents / therapeutic use
-
CCR5 Receptor Antagonists*
-
Cell Line
-
Chemokine CCL5 / analogs & derivatives
-
Chemokine CCL5 / pharmacology*
-
Chemokine CCL5 / therapeutic use
-
Chemokine CXCL12
-
Cytokines / chemistry
-
Cytokines / pharmacology*
-
Cytokines / therapeutic use
-
Genome, Viral
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV-1* / genetics
-
Humans
-
Molecular Sequence Data
-
Receptors, CXCR4 / antagonists & inhibitors*
Substances
-
Anti-HIV Agents
-
CCR5 Receptor Antagonists
-
Chemokine CCL5
-
Chemokine CXCL12
-
Cytokines
-
Receptors, CXCR4
Associated data
-
GENBANK/AF234233
-
GENBANK/AF234234
-
GENBANK/AF234235